Blockade of cannabinoid receptor 1 improves insulin resistance, lipid metabolism, and diabetic nephropathy in db/db mice

D. H. Nam, M. H. Lee, J. E. Kim, H. K. Song, Young Sun Kang, J. E. Lee, H. W. Kim, Jin Joo Cha, Y. Y. Hyun, S. H. Kim, S. Y. Han, K. H. Han, J. Y. Han, Dae-Ryong Cha

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

The endocannabinoid system is important in the pathogenesis of obesity-related metabolic disorders. However, the effect of inhibiting the endocannabinoid system in type 2 diabetic nephropathy is unclear. Therefore, we examined the effect of the cannabinoid (CB)1 receptor antagonist, SR141716, on insulin resistance and diabetic nephropathy in db/db mice. Six-week-old db/db mice were treated with the CB1-specific antagonist SR141716 (10 mg/kg·d) for 3 months. Treatment with SR141716 significantly improved insulin resistance and lipid abnormalities. Concomitantly, CB1 antagonism improved cardiac functional and morphological abnormality, hepatic steatosis, and phenotypic changes of adipocytes into small differentiated forms, associated with increased adiponectin expression and decreased lipid hydroperoxide levels. CB1 receptor was overexpressed in diabetic kidneys, especially in podocytes. Treatment with the SR141716 markedly decreased urinary albumin excretion and mesangial expansion and suppressed profibrotic and proinflammatory cytokine synthesis. Furthermore, SR141716 improved renal lipid metabolism and decreased urinary 8-isoprostane levels, renal lipid hydroperoxide content, and renal lipid content. In cultured podocytes, high-glucose stimulation increased CB1 receptor expression, and SR141716 treatment abolished high-glucose-induced up-regulation of collagen and plasminogen activator inhibitor-1 synthesis. Additionally, knockdown of CB1 receptor expression by stealth small interfering RNA abolished high-glucose-induced sterol-regulatory element-binding protein-1 expression in podocytes. These findings suggest that CB1 blockade improves insulin resistance and protect against renal injury through both metabolic and antifibrotic effects in type 2 diabetic nephropathy. Targeting CB1 blockade could therefore provide a new therapeutic target to prevent type 2 diabetic nephropathy.

Original languageEnglish
Pages (from-to)1387-1396
Number of pages10
JournalEndocrinology
Volume153
Issue number3
DOIs
Publication statusPublished - 2012 Mar 1

Fingerprint

rimonabant
Cannabinoid Receptors
Diabetic Nephropathies
Lipid Metabolism
Insulin Resistance
Cannabinoid Receptor CB1
Podocytes
Kidney
Endocannabinoids
8-epi-prostaglandin F2alpha
Lipid Peroxides
Glucose
Cannabinoid Receptor Antagonists
Sterol Regulatory Element Binding Protein 1
Lipids
Adiponectin
Plasminogen Activator Inhibitor 1
Adipocytes
Small Interfering RNA
Albumins

ASJC Scopus subject areas

  • Endocrinology

Cite this

Blockade of cannabinoid receptor 1 improves insulin resistance, lipid metabolism, and diabetic nephropathy in db/db mice. / Nam, D. H.; Lee, M. H.; Kim, J. E.; Song, H. K.; Kang, Young Sun; Lee, J. E.; Kim, H. W.; Cha, Jin Joo; Hyun, Y. Y.; Kim, S. H.; Han, S. Y.; Han, K. H.; Han, J. Y.; Cha, Dae-Ryong.

In: Endocrinology, Vol. 153, No. 3, 01.03.2012, p. 1387-1396.

Research output: Contribution to journalArticle

Nam, DH, Lee, MH, Kim, JE, Song, HK, Kang, YS, Lee, JE, Kim, HW, Cha, JJ, Hyun, YY, Kim, SH, Han, SY, Han, KH, Han, JY & Cha, D-R 2012, 'Blockade of cannabinoid receptor 1 improves insulin resistance, lipid metabolism, and diabetic nephropathy in db/db mice', Endocrinology, vol. 153, no. 3, pp. 1387-1396. https://doi.org/10.1210/en.2011-1423
Nam, D. H. ; Lee, M. H. ; Kim, J. E. ; Song, H. K. ; Kang, Young Sun ; Lee, J. E. ; Kim, H. W. ; Cha, Jin Joo ; Hyun, Y. Y. ; Kim, S. H. ; Han, S. Y. ; Han, K. H. ; Han, J. Y. ; Cha, Dae-Ryong. / Blockade of cannabinoid receptor 1 improves insulin resistance, lipid metabolism, and diabetic nephropathy in db/db mice. In: Endocrinology. 2012 ; Vol. 153, No. 3. pp. 1387-1396.
@article{1e21f24ab6e843e3b22e2d1581083113,
title = "Blockade of cannabinoid receptor 1 improves insulin resistance, lipid metabolism, and diabetic nephropathy in db/db mice",
abstract = "The endocannabinoid system is important in the pathogenesis of obesity-related metabolic disorders. However, the effect of inhibiting the endocannabinoid system in type 2 diabetic nephropathy is unclear. Therefore, we examined the effect of the cannabinoid (CB)1 receptor antagonist, SR141716, on insulin resistance and diabetic nephropathy in db/db mice. Six-week-old db/db mice were treated with the CB1-specific antagonist SR141716 (10 mg/kg·d) for 3 months. Treatment with SR141716 significantly improved insulin resistance and lipid abnormalities. Concomitantly, CB1 antagonism improved cardiac functional and morphological abnormality, hepatic steatosis, and phenotypic changes of adipocytes into small differentiated forms, associated with increased adiponectin expression and decreased lipid hydroperoxide levels. CB1 receptor was overexpressed in diabetic kidneys, especially in podocytes. Treatment with the SR141716 markedly decreased urinary albumin excretion and mesangial expansion and suppressed profibrotic and proinflammatory cytokine synthesis. Furthermore, SR141716 improved renal lipid metabolism and decreased urinary 8-isoprostane levels, renal lipid hydroperoxide content, and renal lipid content. In cultured podocytes, high-glucose stimulation increased CB1 receptor expression, and SR141716 treatment abolished high-glucose-induced up-regulation of collagen and plasminogen activator inhibitor-1 synthesis. Additionally, knockdown of CB1 receptor expression by stealth small interfering RNA abolished high-glucose-induced sterol-regulatory element-binding protein-1 expression in podocytes. These findings suggest that CB1 blockade improves insulin resistance and protect against renal injury through both metabolic and antifibrotic effects in type 2 diabetic nephropathy. Targeting CB1 blockade could therefore provide a new therapeutic target to prevent type 2 diabetic nephropathy.",
author = "Nam, {D. H.} and Lee, {M. H.} and Kim, {J. E.} and Song, {H. K.} and Kang, {Young Sun} and Lee, {J. E.} and Kim, {H. W.} and Cha, {Jin Joo} and Hyun, {Y. Y.} and Kim, {S. H.} and Han, {S. Y.} and Han, {K. H.} and Han, {J. Y.} and Dae-Ryong Cha",
year = "2012",
month = "3",
day = "1",
doi = "10.1210/en.2011-1423",
language = "English",
volume = "153",
pages = "1387--1396",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "3",

}

TY - JOUR

T1 - Blockade of cannabinoid receptor 1 improves insulin resistance, lipid metabolism, and diabetic nephropathy in db/db mice

AU - Nam, D. H.

AU - Lee, M. H.

AU - Kim, J. E.

AU - Song, H. K.

AU - Kang, Young Sun

AU - Lee, J. E.

AU - Kim, H. W.

AU - Cha, Jin Joo

AU - Hyun, Y. Y.

AU - Kim, S. H.

AU - Han, S. Y.

AU - Han, K. H.

AU - Han, J. Y.

AU - Cha, Dae-Ryong

PY - 2012/3/1

Y1 - 2012/3/1

N2 - The endocannabinoid system is important in the pathogenesis of obesity-related metabolic disorders. However, the effect of inhibiting the endocannabinoid system in type 2 diabetic nephropathy is unclear. Therefore, we examined the effect of the cannabinoid (CB)1 receptor antagonist, SR141716, on insulin resistance and diabetic nephropathy in db/db mice. Six-week-old db/db mice were treated with the CB1-specific antagonist SR141716 (10 mg/kg·d) for 3 months. Treatment with SR141716 significantly improved insulin resistance and lipid abnormalities. Concomitantly, CB1 antagonism improved cardiac functional and morphological abnormality, hepatic steatosis, and phenotypic changes of adipocytes into small differentiated forms, associated with increased adiponectin expression and decreased lipid hydroperoxide levels. CB1 receptor was overexpressed in diabetic kidneys, especially in podocytes. Treatment with the SR141716 markedly decreased urinary albumin excretion and mesangial expansion and suppressed profibrotic and proinflammatory cytokine synthesis. Furthermore, SR141716 improved renal lipid metabolism and decreased urinary 8-isoprostane levels, renal lipid hydroperoxide content, and renal lipid content. In cultured podocytes, high-glucose stimulation increased CB1 receptor expression, and SR141716 treatment abolished high-glucose-induced up-regulation of collagen and plasminogen activator inhibitor-1 synthesis. Additionally, knockdown of CB1 receptor expression by stealth small interfering RNA abolished high-glucose-induced sterol-regulatory element-binding protein-1 expression in podocytes. These findings suggest that CB1 blockade improves insulin resistance and protect against renal injury through both metabolic and antifibrotic effects in type 2 diabetic nephropathy. Targeting CB1 blockade could therefore provide a new therapeutic target to prevent type 2 diabetic nephropathy.

AB - The endocannabinoid system is important in the pathogenesis of obesity-related metabolic disorders. However, the effect of inhibiting the endocannabinoid system in type 2 diabetic nephropathy is unclear. Therefore, we examined the effect of the cannabinoid (CB)1 receptor antagonist, SR141716, on insulin resistance and diabetic nephropathy in db/db mice. Six-week-old db/db mice were treated with the CB1-specific antagonist SR141716 (10 mg/kg·d) for 3 months. Treatment with SR141716 significantly improved insulin resistance and lipid abnormalities. Concomitantly, CB1 antagonism improved cardiac functional and morphological abnormality, hepatic steatosis, and phenotypic changes of adipocytes into small differentiated forms, associated with increased adiponectin expression and decreased lipid hydroperoxide levels. CB1 receptor was overexpressed in diabetic kidneys, especially in podocytes. Treatment with the SR141716 markedly decreased urinary albumin excretion and mesangial expansion and suppressed profibrotic and proinflammatory cytokine synthesis. Furthermore, SR141716 improved renal lipid metabolism and decreased urinary 8-isoprostane levels, renal lipid hydroperoxide content, and renal lipid content. In cultured podocytes, high-glucose stimulation increased CB1 receptor expression, and SR141716 treatment abolished high-glucose-induced up-regulation of collagen and plasminogen activator inhibitor-1 synthesis. Additionally, knockdown of CB1 receptor expression by stealth small interfering RNA abolished high-glucose-induced sterol-regulatory element-binding protein-1 expression in podocytes. These findings suggest that CB1 blockade improves insulin resistance and protect against renal injury through both metabolic and antifibrotic effects in type 2 diabetic nephropathy. Targeting CB1 blockade could therefore provide a new therapeutic target to prevent type 2 diabetic nephropathy.

UR - http://www.scopus.com/inward/record.url?scp=84863116720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863116720&partnerID=8YFLogxK

U2 - 10.1210/en.2011-1423

DO - 10.1210/en.2011-1423

M3 - Article

C2 - 22234468

AN - SCOPUS:84863116720

VL - 153

SP - 1387

EP - 1396

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 3

ER -